TARCEVA Side Effects

7027232-0 | Pulmonary Embolism, Respiratory Failure
on Sep 14, 2010 Male patient from PORTUGAL , 75 years of age, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?), respiratory failure. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

7027227-7 | Adenoma Benign, Blood Magnesium, Bronchial Carcinoma, Computerised Tomogram, Depression, Disability, Facial Paresis, Gastritis, Hyperthyroidism
Patient was taking Tarceva (View Usage). Patient had the following side effects: adenoma benign, blood magnesium, bronchial carcinoma, computerised tomogram, depression (What is depression?), disability, facial paresis, gastritis, hyperthyroidism on Sep 14, 2010 from GERMANY Additional patient health information: Female patient , 54 years of age, was diagnosed with bronchial carcinoma and. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), METHIMAZOLE (View Methimazole Review and Methimazole Label ), NOVALGIN (METAMAZOLE SODIUM) (View Novalgin (metamazole Sodium) Review and Novalgin (metamazole Sodium) Label ), AREDIA (View Aredia Review and Aredia Label ). Patient was hospitalized and became disabled.

7023460-9 | Haemoptysis
Adverse event was reported on Jul 13, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: 150 Mg, Qd, Oral) was diagnosed with lung neoplasm malignant and. Location: UNITED STATES , 60 years of age, After Tarceva was administered, patient had the following side effects: haemoptysis. Patient was hospitalized.

7022251-2 | Ascites, Blood Pressure Decreased, Hyperpyrexia, Inflammation, Interstitial Lung Disease, Lymphocyte Count Increased, Pleural Effusion
on Sep 09, 2010 Male patient from JAPAN , 71 years of age, was diagnosed with lung adenocarcinoma and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, blood pressure decreased, hyperpyrexia, inflammation, interstitial lung disease, lymphocyte count increased, pleural effusion. Tarceva dosage: (100 Mg, Qd), Oral. During the same period patient was treated with PIOGLITAZONE HCL (View Pioglitazone Hcl Review and Pioglitazone Hcl Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), AMARYL (View Amaryl Review and Amaryl Label ), ZOLPIDEM TARTRATE (View Zolpidem Tartrate Review and Zolpidem Tartrate Label ), SENNOSIDE (View Sennoside Review and Sennoside Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ), PHENYTOIN (View Phenytoin Review and Phenytoin Label ), MAXIPIME (View Maxipime Review and Maxipime Label ). Patient was hospitalized.


7018528-7 | Respiratory Failure
on Sep 09, 2010 Male patient from UNITED STATES , 77 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: respiratory failure. Tarceva dosage: 150 Mg, Qd, Oral.

7018341-0 | Alanine Aminotransferase Increased, Antibiotic Resistant Staphylococcus Test Positive, Blood Albumin Decreased, Blood Creatinine Decreased, Candida Test Positive, Carbon Dioxide Decreased, Confusional State, Dyspnoea, Ejection Fraction Decreased
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: alanine aminotransferase increased, antibiotic resistant staphylococcus test positive, blood albumin decreased, blood creatinine decreased, candida test positive, carbon dioxide decreased, confusional state, dyspnoea, ejection fraction decreased on Sep 08, 2010 from UNITED STATES Additional patient health information: Female patient , 46 years of age, was diagnosed with breast cancer (What is breast cancer?) and. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with BENDAMUSTINE (BENDAMUSTINE) (234 Mg, Intravenous) (View Bendamustine (bendamustine) Review and Bendamustine (bendamustine) Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROMORPHONE HCL (View Hydromorphone Hcl Review and Hydromorphone Hcl Label ), ESOMEPRAZOLE (ESOMEPRAZOLE) (View Esomeprazole (esomeprazole) Review and Esomeprazole (esomeprazole) Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), DOCUSATE (DOCUSATE) (View Docusate (docusate) Review and Docusate (docusate) Label ). Patient was hospitalized.

7014316-6 | Coma, Haemoglobin Decreased, Renal Failure Acute
Adverse event was reported on Sep 24, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: ) was diagnosed with lung neoplasm malignant and. Location: UNITED STATES , 79 years of age, weighting 180.0 lb, Patient experienced the following unwanted or unexpected effects: coma, haemoglobin decreased, renal failure acute. Patient was hospitalized.

7009443-3 | Haemoptysis
on Sep 03, 2010 Male patient from UNITED STATES , 60 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient had the following side effects: haemoptysis. Tarceva dosage: (150 Mg,qd), Oral. Patient was hospitalized.

7009142-8 | Body Temperature Increased, Chest X-ray Abnormal, Hypersensitivity, International Normalised Ratio Increased
on Sep 02, 2010 Male patient from UNITED STATES , 76 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: body temperature increased, chest x-ray abnormal, hypersensitivity, international normalised ratio increased. Tarceva dosage: (100 Mg,qd), Oral. During the same period patient was treated with WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), GLIPIZIDE (GLTPIZIDE) (View Glipizide (gltpizide) Review and Glipizide (gltpizide) Label ). Patient was hospitalized.

7008654-0 | Abdominal Pain
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?) on Sep 02, 2010 from ITALY Additional patient health information: Male patient , 61 years of age, was diagnosed with lung neoplasm malignant and. Tarceva dosage: 150 Mg, Qd, Oral.

7008652-7 | Erythema, Lung Neoplasm Malignant, Malignant Neoplasm Progression, Skin Fissures, Vulval Disorder
Adverse event was reported on Sep 03, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg,qd),oral) was diagnosed with lung neoplasm malignant and. Location: NETHERLANDS , 72 years of age, Patient had the following side effects: erythema, lung neoplasm malignant, malignant neoplasm progression, skin fissures, vulval disorder.

7003510-6 | Skin Ulcer
on Aug 31, 2010 Male patient from JAPAN , 69 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: skin ulcer. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6994542-2 | Abdominal Pain
on Sep 15, 2010 Female patient from UNITED STATES , weighting 84.88 lb, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?). Tarceva dosage: 4300 Mg. During the same period patient was treated with GEMCITABINE HCL (8640 Mg) (View Gemcitabine Hcl Review and Gemcitabine Hcl Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ZOCOR (View Zocor Review and Zocor Label ), HYDROCODONE (View Hydrocodone Review and Hydrocodone Label ), DIOVAN (View Diovan Review and Diovan Label ). Patient was hospitalized.

6986492-2 | Leukoencephalopathy
Patient was taking Tarceva (View Usage). Patient had the following side effects: leukoencephalopathy on Aug 26, 2010 from JAPAN Additional patient health information: Female patient , 66 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: Oral.

6986490-9 | Decreased Appetite, Haemoptysis, Interstitial Lung Disease, Lung Disorder, Metastases To Lung, Nausea, Pleural Effusion, Rash, Respiratory Failure
Adverse event was reported on Aug 26, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with lung adenocarcinoma and. Location: JAPAN , 73 years of age, After Tarceva was administered, patient had the following side effects: decreased appetite, haemoptysis, interstitial lung disease, lung disorder, metastases to lung, nausea (What is nausea?), pleural effusion, rash (What is rash?), respiratory failure. During the same period patient was treated with VALTREX (View Valtrex Review and Valtrex Label ), VIDARABINE (VIDARABINE) (View Vidarabine (vidarabine) Review and Vidarabine (vidarabine) Label ), LOXONIN (LOXOPROFEN SODIUM) (View Loxonin (loxoprofen Sodium) Review and Loxonin (loxoprofen Sodium) Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), SIGMART (NICORANDIL) (View Sigmart (nicorandil) Review and Sigmart (nicorandil) Label ), ISOSORBIDE MONONITRATE (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ).

6984651-6 | Eye Disorder
on Aug 26, 2010 Male patient from UNITED STATES , 77 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: eye disorder. Tarceva dosage: (150 Mg, Qd), Oral.

6980190-7 | Electrocardiogram St-t Segment Depression, Prinzmetal Angina
on Aug 23, 2010 Female patient from JAPAN , 71 years of age, weighting 106.3 lb, was diagnosed with lung adenocarcinoma and was treated with Tarceva (View Usage). Patient had the following side effects: electrocardiogram st-t segment depression, prinzmetal angina. Tarceva dosage: 150 Mg, Qd, Oral; 50 Mg, Qd, Oral; 25 Mg, Qd, Oral; 25 Mg, Qd, Oral. During the same period patient was treated with NERIPROCT SUPPOSITORIES (DIFLUCORTOLONE VALERATE) (View Neriproct Suppositories (diflucortolone Valerate) Review and Neriproct Suppositories (diflucortolone Valerate) Label ), POSTERISAN (POSTERISAN) (View Posterisan (posterisan) Review and Posterisan (posterisan) Label ), AMOBAN (ZOPICLONE) (View Amoban (zopiclone) Review and Amoban (zopiclone) Label ), PIRENOXINE (PIRENOXINE) (View Pirenoxine (pirenoxine) Review and Pirenoxine (pirenoxine) Label ), RIKKUNSHI TO (View Rikkunshi-to Review and Rikkunshi-to Label ). Patient was hospitalized.

6971843-5 | Biliary Dilatation, Cholelithiasis, Jaundice Cholestatic, Liver Disorder
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: biliary dilatation, cholelithiasis, jaundice cholestatic, liver disorder on Aug 20, 2010 from JAPAN Additional patient health information: Female patient , 74 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: 100 Mg, Qd, Oral. During the same period patient was treated with OXYCONTIN (View Oxycontin Review and Oxycontin Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), LOXOPROFEN (LOXOPROFEN) (View Loxoprofen (loxoprofen) Review and Loxoprofen (loxoprofen) Label ), ZOLPIDEM TARTRATE (View Zolpidem Tartrate Review and Zolpidem Tartrate Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ). Patient was hospitalized.

6969392-3 | Abscess Intestinal, Large Intestine Perforation, Lung Infection, Metastases To Spine, Pulmonary Embolism, Radiation Pneumonitis
Adverse event was reported on Aug 16, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 150 Mg, Oral) was diagnosed with adenoma benign and. Location: FINLAND , 66 years of age, Patient experienced the following unwanted or unexpected effects: abscess intestinal, large intestine perforation, lung infection, metastases to spine, pulmonary embolism (What is pulmonary embolism?), radiation pneumonitis. During the same period patient was treated with AVASTIN (Intravenous) (View Avastin Review and Avastin Label ). Patient was hospitalized.

6963835-7 | Clostridium Colitis, Depression, Infection, Intervertebral Disc Protrusion
on Aug 12, 2010 Female patient from GERMANY , 72 years of age, was diagnosed with pancreatic carcinoma, infection (What is infection?) and was treated with Tarceva (View Usage). Patient had the following side effects: clostridium colitis, depression (What is depression?), infection (What is infection?), intervertebral disc protrusion. Tarceva dosage: 100 Mg Qd Oral. During the same period patient was treated with PRIMAXIN (500 Mg Tid Intravenous) (View Primaxin Review and Primaxin Label ), GEMCITABINE (1600 Mg Intravenous) (View Gemcitabine Review and Gemcitabine Label ), TETRAZEPAM (TETRAZEPAM) (View Tetrazepam (tetrazepam) Review and Tetrazepam (tetrazepam) Label ), BUPRENORPHINE HYDROCHLORIDE (View Buprenorphine Hydrochloride Review and Buprenorphine Hydrochloride Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), CAPTOPRIL (View Captopril Review and Captopril Label ). Patient was hospitalized.

6962248-1 | Photosensitivity Reaction, Rash Erythematous
on Sep 01, 2010 Female patient from UNITED STATES , 58 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: photosensitivity reaction, rash erythematous. Tarceva dosage: 150mg Once A Day Po.

6956808-1 | Faecal Vomiting, Intestinal Obstruction
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: faecal vomiting, intestinal obstruction on Aug 10, 2010 from VENEZUELA Additional patient health information: Female patient , 79 years of age, was diagnosed with pancreatic carcinoma and. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ).

6955925-X | Blood Pressure Increased, Fall, Ischaemic Cerebral Infarction, Vocal Cord Paralysis
Adverse event was reported on Aug 26, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 150mg Daily Po) was diagnosed with non-small cell lung cancer metastatic and. Location: UNITED STATES , 54 years of age, weighting 128.7 lb, Patient had the following side effects: blood pressure increased, fall (What is fall?), ischaemic cerebral infarction, vocal cord paralysis. During the same period patient was treated with FIBERCON (View Fibercon Review and Fibercon Label ), COUMADIN (View Coumadin Review and Coumadin Label ), MORPHINE (View Morphine Review and Morphine Label ). Patient was hospitalized.

6955096-X | Pleural Effusion, Pneumonia
on Aug 08, 2010 Female patient from UNITED STATES , 80 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: pleural effusion, pneumonia (What is pneumonia?). Tarceva dosage: (100 Mg, Qd), Oral. Patient was hospitalized.

6946767-X | Decreased Appetite, Haemoptysis, Interstitial Lung Disease, Nausea, Rash
on Aug 09, 2010 Male patient from JAPAN , 73 years of age, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: decreased appetite, haemoptysis, interstitial lung disease, nausea (What is nausea?), rash (What is rash?). Tarceva dosage: Mg, Qd, Oral. During the same period patient was treated with VALTREX (View Valtrex Review and Valtrex Label ), VIDARABINE (View Vidarabine Review and Vidarabine Label ), LOXONIN (LOXOPROFEN SODIUM) (View Loxonin (loxoprofen Sodium) Review and Loxonin (loxoprofen Sodium) Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), MUCOSTA (REBAMIPIDE0 (View Mucosta (rebamipide0 Review and Mucosta (rebamipide0 Label ), SIGMART (NICORANDIL) (View Sigmart (nicorandil) Review and Sigmart (nicorandil) Label ), ISOSORBIDE MONONITRATE (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ).

6942266-X |
Patient was taking Tarceva (View Usage). on Aug 05, 2010 from UNITED STATES Additional patient health information: Female patient , 88 years of age, . Tarceva dosage: .

6940402-2 | Retinal Tear
Adverse event was reported on Aug 04, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qod), Oral) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , 58 years of age, After Tarceva was administered, patient had the following side effects: retinal tear.

6940152-2 | Decreased Appetite, Dehydration, Diarrhoea, Disseminated Intravascular Coagulation, Hypophagia, Pneumonia, Rash
on Aug 05, 2010 Male patient from JAPAN , 70 years of age, weighting 40.12 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: decreased appetite, dehydration, diarrhoea, disseminated intravascular coagulation, hypophagia, pneumonia (What is pneumonia?), rash (What is rash?). Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with FAMOTIDINE (View Famotidine Review and Famotidine Label ), LOXONIN (LOXOOROFEN SODIUM) (View Loxonin (loxoorofen Sodium) Review and Loxonin (loxoorofen Sodium) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), TAMSULOSIN HCL (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ), NIFEDIPINE (View Nifedipine Review and Nifedipine Label ).

6939608-8 | Blood Glucose Increased, Haematocrit Decreased, Haemoglobin Decreased, Red Blood Cell Count Decreased, Rhabdomyolysis
on Aug 05, 2010 Male patient from GERMANY , 73 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). Patient had the following side effects: blood glucose increased, haematocrit decreased, haemoglobin decreased, red blood cell count decreased, rhabdomyolysis. Tarceva dosage: (100 Mg,qd),oral. During the same period patient was treated with GEMCITABINE ((1640 Mg 1x Per 3 Week),intravenous) (View Gemcitabine Review and Gemcitabine Label ). Patient was hospitalized.

6939516-2 | Skin Mass
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: skin mass on Aug 03, 2010 from JAPAN Additional patient health information: Female patient , 77 years of age, . Tarceva dosage: Oral.

6937731-5 | Abdominal Distension, Cardiac Arrest, Gastrointestinal Disorder, Pain, Respiratory Distress, Sepsis, Tachypnoea, Ventricular Fibrillation, Vomiting
Adverse event was reported on Aug 20, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer metastatic and. Location: UNITED STATES , 76 years of age, weighting 160.3 lb, Patient experienced the following unwanted or unexpected effects: abdominal distension, cardiac arrest (What is cardiac arrest?), gastrointestinal disorder, pain (What is pain?), respiratory distress, sepsis (What is sepsis?), tachypnoea, ventricular fibrillation, vomiting.

6936431-5 | Adverse Event
on Aug 02, 2010 Male patient from UNITED STATES , 70 years of age, was diagnosed with pancreatic carcinoma and was treated with Tarceva (View Usage). Patient had the following side effects: adverse event. Tarceva dosage: 150 Mg, Qd, Oral. Patient was hospitalized.

6931136-9 | Respiratory Failure
on Jul 30, 2010 Male patient from UNITED STATES , 70 years of age, was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: respiratory failure. Tarceva dosage: (150 Mg,qd),oral.

6929808-5 | Anuria, Diarrhoea
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: anuria, diarrhoea on Jul 30, 2010 from BELGIUM Additional patient health information: Male patient , 64 years of age, was diagnosed with non-small cell lung cancer and. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), VALPROATE SODIUM (View Valproate Sodium Review and Valproate Sodium Label ).

6929793-6 | Condition Aggravated, Enterovesical Fistula, Metastases To Central Nervous System, Non-small Cell Lung Cancer Metastatic, Rectal Perforation
Adverse event was reported on Jul 29, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) was diagnosed with non-small cell lung cancer, metastases to central nervous system and. Location: GERMANY , 68 years of age, Patient had the following side effects: condition aggravated, enterovesical fistula, metastases to central nervous system, non-small cell lung cancer metastatic, rectal perforation. During the same period patient was treated with DEXAMETHASONE SODIUM POSPHATE ((4 Mg, 2 In 1 D), Oral) (View Dexamethasone Sodium Posphate Review and Dexamethasone Sodium Posphate Label ).

6928908-3 | Skin Mass
on Jul 28, 2010 Female patient from JAPAN , 77 years of age, was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: skin mass. Tarceva dosage: Oral.

6925830-3 | Abdominal Pain, Cough, Dyspnoea, Dysuria, Lethargy
on Aug 13, 2010 Female patient from UNITED STATES , weighting 134.5 lb, was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), cough, dyspnoea, dysuria, lethargy. Tarceva dosage: 6150 M. Patient was hospitalized.

6924934-9 | Hypophagia, Hypotension, Pulmonary Embolism, Sepsis, Septic Shock
Patient was taking Tarceva (View Usage). Patient had the following side effects: hypophagia, hypotension, pulmonary embolism (What is pulmonary embolism?), sepsis (What is sepsis?), septic shock on Jul 27, 2010 from AUSTRALIA Additional patient health information: Female patient , 76 years of age, . Tarceva dosage: 100 Mg, Oral. During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), ATACAND (View Atacand Review and Atacand Label ), INDAPAMIDE (View Indapamide Review and Indapamide Label ), LIPITOR (View Lipitor Review and Lipitor Label ), CALTRATE (CALCIUM CARBONATE) (View Caltrate (calcium Carbonate) Review and Caltrate (calcium Carbonate) Label ).

6924927-1 | Disease Progression, Erythema, Skin Fissures, Vulval Disorder
Adverse event was reported on Jul 27, 2010 by a Female patient taking Tarceva (View Usage) (Dosage: 150 Mg, Qd, Oral) was diagnosed with lung neoplasm malignant and. Location: NETHERLANDS , 72 years of age, After Tarceva was administered, patient had the following side effects: disease progression, erythema, skin fissures, vulval disorder.

6922707-4 | Fall, Head Injury, Laceration, Rib Fracture
on Jul 27, 2010 Male patient from UNITED STATES , 78 years of age, was diagnosed with bronchial carcinoma and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: fall (What is fall?), head injury, laceration, rib fracture. Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6922630-5 | Bronchial Haemorrhage, Haemoptysis
on Jul 26, 2010 Male patient from UNITED STATES , 63 years of age, weighting 184.0 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). Patient had the following side effects: bronchial haemorrhage, haemoptysis. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with ALTACE (View Altace Review and Altace Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ).

6919541-8 | Blood Culture Positive, Cholangitis, Decreased Appetite, Interstitial Lung Disease, Multi-organ Disorder, Staphylococcal Infection
Patient was taking Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: blood culture positive, cholangitis, decreased appetite, interstitial lung disease, multi-organ disorder, staphylococcal infection (What is staphylococcal infection?) on Jul 23, 2010 from JAPAN Additional patient health information: Female patient , 76 years of age, was diagnosed with lung adenocarcinoma and. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), COLDRIN (CLOFEDANOL HYDROCHLORIDE) (View Coldrin (clofedanol Hydrochloride) Review and Coldrin (clofedanol Hydrochloride) Label ), MUCODYNE (CARBOCISTEINE) (View Mucodyne (carbocisteine) Review and Mucodyne (carbocisteine) Label ).

6917563-4 | Cardiac Failure Acute, Orthopnoea, Tachypnoea
Adverse event was reported on Jul 22, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: (150 Mg), Oral) was diagnosed with lung neoplasm malignant and. Location: CHINA , 72 years of age, Patient experienced the following unwanted or unexpected effects: cardiac failure acute, orthopnoea, tachypnoea.

6917249-6 | Epistaxis, Haemoglobin Decreased, International Normalised Ratio Increased, Malignant Neoplasm Progression, Pulmonary Alveolar Haemorrhage, Renal Haemorrhage
on Jul 21, 2010 Male patient from JAPAN , 68 years of age, weighting 133.2 lb, was diagnosed with lung adenocarcinoma and was treated with Tarceva (View Usage). Patient had the following side effects: epistaxis, haemoglobin decreased, international normalised ratio increased, malignant neoplasm progression, pulmonary alveolar haemorrhage, renal haemorrhage. Tarceva dosage: 150 Mg, Qd, Oral. During the same period patient was treated with WARFARIN POTASSIUM (WARFARIN POTASSIUM) (Oral) (View Warfarin Potassium (warfarin Potassium) Review and Warfarin Potassium (warfarin Potassium) Label ), VALSARTAN (View Valsartan Review and Valsartan Label ), URIEF (View Urief Review and Urief Label ), ZANTAC 150 (View Zantac 150 Review and Zantac 150 Label ). Patient was hospitalized.

6916909-0 | Anxiety, Tremor
on Aug 09, 2010 Male patient from UNITED STATES , 84 years of age, weighting 207.0 lb, was diagnosed with non-small cell lung cancer and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: anxiety (What is anxiety?), tremor. Tarceva dosage: 150mg,daily,oral.

6916838-2 | Rash
Patient was taking Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: rash (What is rash?) on Aug 09, 2010 from UNITED STATES Additional patient health information: Male patient , 84 years of age, weighting 207.0 lb, was diagnosed with non-small cell lung cancer and. Tarceva dosage: 150mg, Daily, Oral. During the same period patient was treated with RADIATION TREATMENT (View Radiation Treatment Review and Radiation Treatment Label ).

6908977-7 | Lung Neoplasm Malignant, Malignant Neoplasm Progression, Rash, Respiratory Distress
Adverse event was reported on Jul 19, 2010 by a Male patient taking Tarceva (View Usage) (Dosage: (150 Mg, Qd), Oral) . Location: UNITED STATES , 63 years of age, Patient had the following side effects: lung neoplasm malignant, malignant neoplasm progression, rash (What is rash?), respiratory distress. During the same period patient was treated with HYDROCODONE BITARTRATE (View Hydrocodone Bitartrate Review and Hydrocodone Bitartrate Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), BACLOFEN (View Baclofen Review and Baclofen Label ), CALMOSEPTINE (View Calmoseptine Review and Calmoseptine Label ), CELEXA (View Celexa Review and Celexa Label ), COLACE (DOCUSATE SODIUM) (View Colace (docusate Sodium) Review and Colace (docusate Sodium) Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ). Patient was hospitalized.

6908953-4 | Bronchial Haemorrhage, Haemoptysis
on Jul 19, 2010 Male patient from UNITED STATES , 63 years of age, weighting 184.0 lb, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). After Tarceva was administered, patient had the following side effects: bronchial haemorrhage, haemoptysis. Tarceva dosage: (150 Mg, Qd), Oral. During the same period patient was treated with ALTACE (View Altace Review and Altace Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).

6905736-6 | Anaemia, Dehydration, Lung Cancer Metastatic, Lung Neoplasm Malignant, Malignant Neoplasm Progression, Oesophageal Infection, Rash
on Jul 14, 2010 Male patient from UNITED STATES , 85 years of age, was diagnosed with lung neoplasm malignant and was treated with Tarceva (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, dehydration, lung cancer metastatic, lung neoplasm malignant, malignant neoplasm progression, oesophageal infection, rash (What is rash?). Tarceva dosage: (150 Mg, Qd), Oral. Patient was hospitalized.

6902519-8 | Blood Bilirubin Increased, Decreased Appetite, Dehydration, Depressed Level Of Consciousness, Gastric Ulcer Haemorrhage, Pulmonary Embolism, Rash
Patient was taking Tarceva (View Usage). Patient had the following side effects: blood bilirubin increased, decreased appetite, dehydration, depressed level of consciousness, gastric ulcer haemorrhage, pulmonary embolism (What is pulmonary embolism?), rash (What is rash?) on Jul 15, 2010 from JAPAN Additional patient health information: Male patient , 75 years of age, . Tarceva dosage: (150 Mg,qd),oral. During the same period patient was treated with TS 1 (View Ts-1 Review and Ts-1 Label ), WINTERMIN (CHLORPROMAZINE) (View Wintermin (chlorpromazine) Review and Wintermin (chlorpromazine) Label ), MIYARI BACTERIA (MIYARI BACTERIA) (View Miyari Bacteria (miyari Bacteria) Review and Miyari Bacteria (miyari Bacteria) Label ), ROHYPNOL (FLUNITRAZEPAM) (View Rohypnol (flunitrazepam) Review and Rohypnol (flunitrazepam) Label ), LOXOPROFEN (LOXOPROFEN) (View Loxoprofen (loxoprofen) Review and Loxoprofen (loxoprofen) Label ), AMOXAPINE (View Amoxapine Review and Amoxapine Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ). Patient was hospitalized.